5 tulemused
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of Application No. PCT/EP2007/052081, filed 6 Mar. 2007 (hereby incorporated by reference herein), which application claims priority from EPO Patent Application No. 06110745.4, filed 7 Mar., 2006.
The present invention
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national stage application of Patent Application No. PCT/EP2008/061765, filed 5 Sep. 2008, which in turn claims the benefit of EPO Patent Application No. 07115876.0 filed 7 Sep. 2007. The complete disclosures of the aforementioned related
BACKGROUND OF THE INVENTION
Cystic Fibrosis (CF) is the most common inheritable lethal disease among Caucasians. There are approximately 25,000 CF patients in the U.S.A. The frequency of CF in several other countries (e.g., Canada, United Kingdom, Denmark) is high (ranging from 1 in 400 to 1 in
BACKGROUND OF THE INVENTION
Cystic Fibrosis (CF) is the most common inheritable lethal disease among Caucasians. There are approximately 25,000 CF patients in the U.S.A. The frequency of CF in several other countries (e.g., Canada, United Kingdom, Denmark) is high (ranging from 1 in 400 to 1 in
BACKGROUND OF THE INVENTION
Cystic Fibrosis (CF) is the most common inheritable lethal disease among caucasians. There are approximately 25,000 CF patients in the U.S.A. The frequency of CF in several other countries (e.g., Canada, United Kingdom, Denmark) is high (ranging from 1 in 400 to 1 in